363 related articles for article (PubMed ID: 19305137)
1. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
[TBL] [Abstract][Full Text] [Related]
4. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
5. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
7. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
8. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
9. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
10. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
11. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
[TBL] [Abstract][Full Text] [Related]
12. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
13. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
14. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
15. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
16. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
Linke K; Mace PD; Smith CA; Vaux DL; Silke J; Day CL
Cell Death Differ; 2008 May; 15(5):841-8. PubMed ID: 18219319
[TBL] [Abstract][Full Text] [Related]
17. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
18. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
19. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
